Tim Evans
Stock Analyst at Wells Fargo
(2.72)
# 1,973
Out of 4,670 analysts
29
Total ratings
78.57%
Success rate
10.74%
Average return
Main Sectors:
Stocks Rated by Tim Evans
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTLT Catalent | Maintains: Equal-Weight | $50 → $42 | $60.98 | -31.12% | 6 | Nov 16, 2023 | |
| BIO Bio-Rad Laboratories | Maintains: Outperform | $290 → $280 | $332.91 | -15.89% | 2 | Feb 28, 2018 | |
| BIO.B Bio-Rad Laboratories | Maintains: Outperform | $290 → $280 | $334.85 | -16.38% | 2 | Feb 28, 2018 | |
| MEDP Medpace Holdings | Maintains: Market Perform | $38 → $35 | $337.75 | -89.64% | 3 | Feb 28, 2018 | |
| ILMN Illumina | Upgrades: Outperform | n/a | $140.14 | - | 2 | Jan 2, 2018 | |
| WST West Pharmaceutical Services | Maintains: Outperform | $105 → $112 | $316.59 | -64.62% | 4 | Oct 27, 2017 | |
| DGX Quest Diagnostics | Maintains: Market Perform | $88 → $86 | $163.59 | -47.43% | 2 | Oct 20, 2017 | |
| LH Labcorp Holdings | Reinstates: Outperform | $175 | $239.67 | -26.98% | 1 | Oct 12, 2017 | |
| TECH Bio-Techne | Initiates: Market Perform | n/a | $71.28 | - | 1 | Jul 13, 2017 | |
| DHR Danaher | Initiates: Market Perform | $90 | $235.84 | -61.84% | 1 | Jul 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1,217.97 | - | 1 | Jul 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $57.07 | - | 2 | Jul 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $133.84 | - | 1 | Jul 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.35 | - | 1 | May 3, 2017 |
Catalent
Nov 16, 2023
Maintains: Equal-Weight
Price Target: $50 → $42
Current: $60.98
Upside: -31.12%
Bio-Rad Laboratories
Feb 28, 2018
Maintains: Outperform
Price Target: $290 → $280
Current: $332.91
Upside: -15.89%
Bio-Rad Laboratories
Feb 28, 2018
Maintains: Outperform
Price Target: $290 → $280
Current: $334.85
Upside: -16.38%
Medpace Holdings
Feb 28, 2018
Maintains: Market Perform
Price Target: $38 → $35
Current: $337.75
Upside: -89.64%
Illumina
Jan 2, 2018
Upgrades: Outperform
Price Target: n/a
Current: $140.14
Upside: -
West Pharmaceutical Services
Oct 27, 2017
Maintains: Outperform
Price Target: $105 → $112
Current: $316.59
Upside: -64.62%
Quest Diagnostics
Oct 20, 2017
Maintains: Market Perform
Price Target: $88 → $86
Current: $163.59
Upside: -47.43%
Labcorp Holdings
Oct 12, 2017
Reinstates: Outperform
Price Target: $175
Current: $239.67
Upside: -26.98%
Bio-Techne
Jul 13, 2017
Initiates: Market Perform
Price Target: n/a
Current: $71.28
Upside: -
Danaher
Jul 13, 2017
Initiates: Market Perform
Price Target: $90
Current: $235.84
Upside: -61.84%
Jul 13, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1,217.97
Upside: -
Jul 13, 2017
Downgrades: Underperform
Price Target: n/a
Current: $57.07
Upside: -
Jul 13, 2017
Upgrades: Outperform
Price Target: n/a
Current: $133.84
Upside: -
May 3, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $1.35
Upside: -